Boehringer Ingelheim Drug Patent Portfolio

Boehringer Ingelheim owns 26 orange book drugs protected by 188 US patents with Aggrenox having the least patent protection, holding only 1 patent. And Spiriva Respimat with maximum patent protection, holding 39 patents. Given below is the list of Boehringer Ingelheim's drug patents along with their expiration dates.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US9949998	Pharmaceutical composition, methods for treating and uses thereof	11 Dec, 2034	Active
US9949997	Pharmaceutical composition, methods for treating and uses thereof	17 Nov, 2034	Active
US10258637	Pharmaceutical composition, methods for treating and uses thereof	03 Oct, 2034	Active
US11090323	Pharmaceutical composition, methods for treating and uses thereof	03 Oct, 2034	Active
US9949998	Pharmaceutical composition, methods for treating and uses thereof	11 Jun, 2034	Active
US9949997	Pharmaceutical composition, methods for treating and uses thereof	17 May, 2034	Active
US10258637	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034	Active
US11090323	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034	Active
US11833166	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034	Active
US11666590	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034	Active
US11813275	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034	Active
US9555001	Pharmaceutical composition and uses thereof	06 Sep, 2033	Active
US9555001	Pharmaceutical composition and uses thereof	06 Mar, 2033	Active
US10596120	Pharmaceutical compositions	07 Sep, 2032	Active
US10596120	Pharmaceutical compositions	07 Mar, 2032	Active
US11564886	Pharmaceutical compositions	07 Mar, 2032	Active
US8853156	Treatment for diabetes in patients inappropriate for metformin therapy	05 Sep, 2031	Active
US9034822	Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds	20 Jul, 2031	Active
US8733341	Atomizer and method of atomizing fluid with a nozzle rinsing mechanism	16 Apr, 2031	Active
US10610489	Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof	30 Mar, 2031	Active
US8853156	Treatment for diabetes in patients inappropriate for metformin therapy	05 Mar, 2031	Active
US9034822	Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds	20 Jan, 2031	Active
US10004743	Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient	05 Jan, 2031	Active
US8846695	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor	04 Dec, 2030	Active
US9155705	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	21 Nov, 2030	Active
US8733341	Atomizer and method of atomizing fluid with a nozzle rinsing mechanism	16 Oct, 2030	Active
US10610489	Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof	30 Sep, 2030	Active
US10004743	Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient	05 Jul, 2030	Active
US8545884	Solid pharmaceutical formulations comprising BIBW 2992	19 Jun, 2030	Active
US10406172	Pharmaceutical composition, methods for treating and uses thereof	15 Jun, 2030	Active
US8846695	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor	04 Jun, 2030	Active
US9155705	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	21 May, 2030	Active
US9010323	Inhaler and sieve for an inhaler	19 Apr, 2030	Active
US8551957	Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate	14 Apr, 2030	Active
US8426586	Process for preparing amino crotonyl compounds	10 Apr, 2030	Active
US11911388	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug	10 Apr, 2030	Active
US12115179	Pharmaceutical composition, methods for treating and uses thereof	11 Feb, 2030	Active
US10034877	Treatment for diabetes in patients inappropriate for metformin therapy	05 Feb, 2030	Active
US9486526	Treatment for diabetes in patients inappropriate for metformin therapy	05 Feb, 2030	Active
US8474447	Inhaler device	17 Jan, 2030	Active
US8545884	Solid pharmaceutical formulations comprising BIBW 2992	19 Dec, 2029	Active
US9907756	Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative	07 Dec, 2029	Active
US10105323	Pharmaceutical dosage form for immediate release of an indolinone derivative	04 Dec, 2029	Active
US8551957	Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate	14 Oct, 2029	Active
US8426586	Process for preparing amino crotonyl compounds	10 Oct, 2029	Active
US10022379	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	02 Oct, 2029	Active
US10973827	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	02 Oct, 2029	Active
US9415016	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	02 Oct, 2029	Active
US8679533	Pramipexole once-daily dosage form	08 Sep, 2029	Active
US10034877	Treatment for diabetes in patients inappropriate for metformin therapy	05 Aug, 2029	Active
US9486526	Treatment for diabetes in patients inappropriate for metformin therapy	05 Aug, 2029	Active
US9907756	Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative	07 Jun, 2029	Active
US10105323	Pharmaceutical dosage form for immediate release of an indolinone derivative	04 Jun, 2029	Active
US10022379	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	02 Apr, 2029	Active
US10973827	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	02 Apr, 2029	Active
US9415016	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	02 Apr, 2029	Active
US8460704	Extended release formulation of nevirapine	12 Mar, 2029	Active
US7579449	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture	01 Feb, 2029	Active
US7837235	Device for clamping a fluidic component	13 Sep, 2028	Active
US7579449	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture	01 Aug, 2028	Active
US7695734	Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof	26 Apr, 2028	Active
US7837235	Device for clamping a fluidic component	13 Mar, 2028	Active
US7866474	Film container	02 Mar, 2028	Active
US11033552	DPP IV inhibitor formulations	04 Nov, 2027	Active
US8673927	Uses of DPP-IV inhibitors	04 Nov, 2027	Active
US9173859	Uses of DPP IV inhibitors	04 Nov, 2027	Active
US7713938	Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments	15 Oct, 2027	Active
US9027967	Device for clamping a fluidic component	30 Sep, 2027	Active
US7694676	Dry powder inhaler	12 Sep, 2027	Active
US7866474	Film container	31 Aug, 2027	Active
US9539258	Quinazoline derivatives for the treatment of cancer diseases	09 May, 2027	Active
US11033552	DPP IV inhibitor formulations	04 May, 2027	Active
US12178819	DPP IV inhibitor formulations	04 May, 2027	Active
US8673927	Uses of DPP-IV inhibitors	04 May, 2027	Active
US9173859	Uses of DPP IV inhibitors	04 May, 2027	Active
US7713938	Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments	15 Apr, 2027	Active
US7396341	Blocking device for a locking stressing mechanism having a spring-actuated output drive device	10 Apr, 2027	Active
US9027967	Device for clamping a fluidic component	31 Mar, 2027	Active
US7694676	Dry powder inhaler	12 Mar, 2027	Active
US7727984	Medicaments for the treatment of chronic obstructive pulmonary disease	19 Jan, 2027	Active
US9539258	Quinazoline derivatives for the treatment of cancer diseases	09 Nov, 2026	Active
US7396341	Blocking device for a locking stressing mechanism having a spring-actuated output drive device	10 Oct, 2026	Active
US8022082	Method for the administration of an anticholinergic by inhalation	19 Jul, 2026	Active
USRE43431	Quinazoline derivatives and pharmaceutical compositions containing them	13 Jul, 2026	Active
US10154990	Medicaments for the treatment or prevention of fibrotic diseases	08 Jul, 2026	Active
US8883805	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	26 May, 2026	Active
US6762180	Substituted indolines which inhibit receptor tyrosine kinases	01 Apr, 2026	Active
US7932273	3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament	07 Mar, 2026	Active
US8022082	Method for the administration of an anticholinergic by inhalation	19 Jan, 2026	Active
USRE43431	Quinazoline derivatives and pharmaceutical compositions containing them	13 Jan, 2026	Active
US10154990	Medicaments for the treatment or prevention of fibrotic diseases	08 Jan, 2026	Active
US8883805	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	26 Nov, 2025	Active
US7896264	Microstructured high pressure nozzle with built-in filter function	26 Nov, 2025	Active
US7407955	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	02 Nov, 2025	Active
US6762180	Substituted indolines which inhibit receptor tyrosine kinases	01 Oct, 2025	Active
US7932273	3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament	07 Sep, 2025	Active
US7896264	Microstructured high pressure nozzle with built-in filter function	26 May, 2025	Active
US7220742	Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments	12 May, 2025	Active
US8034809	Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments	12 May, 2025	Active
US7407955	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	02 May, 2025	Expired
US7284474	Piston-pumping system having o-ring seal properties	26 Feb, 2025	Expired
US7284474	Piston-pumping system having o-ring seal properties	26 Aug, 2024	Expired
US7989474	Use of Lck inhibitors for treatment of immunologic diseases	06 Apr, 2024	Expired
US7119093	3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition	21 Feb, 2024	Expired
US9925174	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof	14 Dec, 2023	Expired
US7056916	Medicaments for the treatment of chronic obstructive pulmonary disease	07 Dec, 2023	Expired
US7491719	Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments	10 Nov, 2023	Expired
US7786111	Medicaments for the treatment of chronic obstructive pulmonary disease	10 Nov, 2023	Expired
US8044046	Medicaments for the treatment of chronic obstructive pulmonary disease	10 Nov, 2023	Expired
US8119648	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	12 Aug, 2023	Expired
US8178541	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	12 Aug, 2023	Expired
US9925174	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof	14 Jun, 2023	Expired
US8003679	Use of inhibitors of the renin-angiotensin system	06 Oct, 2022	Expired
US7070800	Inhalable powder containing tiotropium	22 Jul, 2022	Expired
US6087380	Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions	28 Jun, 2022	Expired
USRE38912	Process for preparing powder formulations	11 Apr, 2022	Expired
US6777423	Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions	24 Mar, 2022	Expired
US6908928	Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions	24 Mar, 2022	Expired
US7309707	Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament	24 Mar, 2022	Expired
US7642268	Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament	24 Mar, 2022	Expired
US7988001	Container provided with a pressure equalization opening	04 Feb, 2022	Expired
US7070800	Inhalable powder containing tiotropium	22 Jan, 2022	Expired
US6087380	Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions	28 Dec, 2021	Expired
USRE38912	Process for preparing powder formulations	11 Oct, 2021	Expired
US6777423	Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions	24 Sep, 2021	Expired
US6908928	Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions	24 Sep, 2021	Expired
US7309707	Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament	24 Sep, 2021	Expired
US7642268	Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament	24 Sep, 2021	Expired
US7988001	Container provided with a pressure equalization opening	04 Aug, 2021	Expired
US6988496	Cartridge for a liquid	23 Aug, 2020	Expired
US6488962	Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms	20 Jun, 2020	Expired
US7998953	Use of inhibitors of the renin-angiotensin system	06 Jun, 2020	Expired
US6739333	Stainless steel canister for propellant-driven metering aerosols	26 May, 2020	Expired
US6983743	Stainless steel canister for propellant-driven metering aerosols	26 May, 2020	Expired
US6147095	Method for improving the pharmacokinetics of tipranavir	29 Apr, 2020	Expired
US6988496	Cartridge for a liquid	23 Feb, 2020	Expired
US6358986	Polymorphs of telmisartan	10 Jan, 2020	Expired
US5852195	Pyranone compounds useful to treat retroviral infections	22 Dec, 2019	Expired
US6147095	Method for improving the pharmacokinetics of tipranavir	29 Oct, 2019	Expired
US7802568	Cartridge for a liquid	26 Aug, 2019	Expired
US5852195	Pyranone compounds useful to treat retroviral infections	22 Jun, 2019	Expired
US6846413	Microstructured filter	28 Feb, 2019	Expired
US6977042	Microstructured filter	28 Feb, 2019	Expired
US7802568	Cartridge for a liquid	26 Feb, 2019	Expired
US6890898	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019	Expired
US7078381	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019	Expired
US7459428	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019	Expired
US6231887	Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation	27 Jan, 2019	Expired
US6846413	Microstructured filter	28 Aug, 2018	Expired
US6977042	Microstructured filter	28 Aug, 2018	Expired
USRE39820	Esters of thienyl carboxylic acids and amino alcohols and their quaternization products	30 Jul, 2018	Expired
US6251912	Substituted quinazoline derivatives	29 Jul, 2018	Expired
US6231887	Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation	27 Jul, 2018	Expired
USRE39820	Esters of thienyl carboxylic acids and amino alcohols and their quaternization products	30 Jan, 2018	Expired
US6001861	Use of pramipexole in the treatment of restless legs syndrome	16 Jan, 2018	Expired
US6194445	Use of pramipexole in the treatment of restless legs syndrome	16 Jan, 2018	Expired
US6149054	Mechanical counter for a metering apparatus	19 Jun, 2017	Expired
US6453795	Locking mechanism for a spring-actuated device	05 Jun, 2017	Expired
US6303661	Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals	24 Apr, 2017	Expired
US5964416	Device for producing high pressure in a fluid in miniature	04 Apr, 2017	Expired
US6726124	Device for producing high pressure in a fluid in miniature	04 Apr, 2017	Expired
US7104470	Device for producing high pressure in a fluid in miniature	04 Apr, 2017	Expired
US6015577	Pharmaceutical compositions containing dipyridamole or mopidamol and acetylsalicylic acid or the physiologically acceptable salts thereof, processes for preparing them and their use in treating clot formation	18 Jan, 2017	Expired
US6149054	Mechanical counter for a metering apparatus	19 Dec, 2016	Expired
US6453795	Locking mechanism for a spring-actuated device	05 Dec, 2016	Expired
US6176442	Device for mounting a component exposed to a pressurized fluid	01 Dec, 2016	Expired
US7246615	Atomising nozzle and filter and spray generating device	01 Dec, 2016	Expired
US5964416	Device for producing high pressure in a fluid in miniature	04 Oct, 2016	Expired
US6176442	Device for mounting a component exposed to a pressurized fluid	04 Oct, 2016	Expired
US6726124	Device for producing high pressure in a fluid in miniature	04 Oct, 2016	Expired
US7104470	Device for producing high pressure in a fluid in miniature	04 Oct, 2016	Expired
US6340475	Extending the duration of drug release within the stomach during the fed mode	19 Sep, 2016	Expired
US6635280	Extending the duration of drug release within the stomach during the fed mode	19 Sep, 2016	Expired
US7246615	Atomising nozzle and filter and spray generating device	31 May, 2016	Expired
US6176242	Method of treating manic depression by brain infusion	31 May, 2016	Expired
US5603918	Aerosol composition of a salt of ipratropium and a salt of albuterol	09 Jun, 2015	Expired
US6169181	Compounds useful to treat retroviral infections	06 Nov, 2014	Expired
US5683677	Medicinal aerosol formulations	04 Nov, 2014	Expired
US5676930	Stabilized medicinal aerosol solution formulations	14 Oct, 2014	Expired
US5662271	Atomizing devices and methods	02 Sep, 2014	Expired
US6169181	Compounds useful to treat retroviral infections	06 May, 2014	Expired
US5591762	Benzimidazoles useful as angiotensin-11 antagonists	07 Jan, 2014	Expired
US5472143	Atomising nozzle and filter and spray generation device	29 Sep, 2013	Expired
US5911851	Atomizing nozzle and filter and spray generating device	29 Sep, 2013	Expired
US6007676	Atomizing nozzle and filter and spray generating device	29 Sep, 2013	Expired
US6503362	Atomizing nozzle an filter and spray generating device	29 Sep, 2013	Expired
US5497944	Atomising devices and methods	12 Mar, 2013	Expired
US5478578	Powders for inhalation	26 Dec, 2012	Expired

Latest Legal Activities on Boehringer Ingelheim's Drug Patents

Given below is the list of recent legal activities going on the following drug patents of Boehringer Ingelheim.

Activity	Date	Patent Number

Payment of Maintenance Fee, 8th Year, Large Entity	05 Jul, 2024	US9539258
Expire Patent Critical	17 Jun, 2024	US8178541
Expire Patent Critical	17 Jun, 2024	US8178541
Expire Patent Critical	17 Jun, 2024	US8178541
Payment of Maintenance Fee, 8th Year, Large Entity	02 May, 2024	US9486526
Expire Patent Critical	25 Mar, 2024	US8119648
Expire Patent Critical	25 Mar, 2024	US8119648
Expire Patent Critical	25 Mar, 2024	US8119648
Mail Patent eGrant Notification	27 Feb, 2024	US11911388
Patent eGrant Notification	27 Feb, 2024	US11911388
Recordation of Patent eGrant	27 Feb, 2024	US11911388
Recordation of Patent Grant Mailed Critical	27 Feb, 2024	US11911388
Patent Issue Date Used in PTA Calculation Critical	27 Feb, 2024	US11911388
Email Notification Critical	27 Feb, 2024	US11911388
Mail Patent eGrant Notification	27 Feb, 2024	US11911388

Boehringer Ingelheim's Drug Patent Litigations

Boehringer Ingelheim's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Sep 26, 2011, against patent number US8679533. The petitioner , challenged the validity of this patent, with Ernest J. Lee et al as the respondent. Click below to track the latest information on how companies are challenging Boehringer Ingelheim's patents.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8853156	August, 2016	Terminated (01 Aug, 2017)	Boehringer Ingelheim Pharmaceuticals Inc. et al.	Mylan Pharmaceuticals Inc. et al.
US8673927	August, 2016	Terminated (18 Jul, 2017)	Boehringer Ingelheim Pharmaceuticals Inc. et al.	Mylan Pharmaceuticals Inc. et al.
US8846695	August, 2016	Terminated (18 Jul, 2017)	Boehringer Ingelheim Pharmaceuticals Inc. et al.	Mylan Pharmaceuticals Inc. et al.
US9173859	August, 2016	Terminated-Denied (03 Feb, 2017)	Boehringer Ingelheim Pharmaceuticals Inc.	Mylan Pharmaceuticals Inc.
US6340475	April, 2014	Final Written Decision (21 Sep, 2015)	Depomed, Inc.	Endo Pharmaceutical Inc. et al.
US6635280	April, 2014	Final Written Decision (21 Sep, 2015)	Depomed, Inc.	Endo Pharmaceutical Inc. et al.
US6340475	January, 2014	FWD Entered (08 Jul, 2015)	Depomed, Inc.	Purdue Pharma L.P.
US6635280	January, 2014	FWD Entered (08 Jul, 2015)	DepoMed, Inc.	Purdue Pharma L.P.
US6340475	April, 2014	Institution Denied (29 Sep, 2014)	Depomed, Inc.	Endo Pharmaceutical Inc. et al.
US6635280	April, 2014	Institution Denied (29 Sep, 2014)	Depomed, Inc.	Endo Pharmaceutical Inc. et al.
US8679533	September, 2011	Decision (22 Oct, 2013)	Ernest J. Lee et al

Boehringer Ingelheim Drug Patents' Oppositions Filed in EPO

Boehringer Ingelheim drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 06, 2006, by Speedel Pharma Ag. This opposition was filed on patent number EP98947698A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status

EP11179908A	Apr, 2023	Generics [UK] Limited	Granted and Under Opposition
EP11179908A	Apr, 2023	STADA Arzneimittel AG	Granted and Under Opposition
EP11179908A	Apr, 2023	Kraus & Weisert Patentanwälte PartGmbB	Granted and Under Opposition
EP14715274A	Apr, 2023	TEVA PHARMACEUTICAL INDUSTRIES, LTD.	Granted and Under Opposition
EP11179908A	Apr, 2023	ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.	Granted and Under Opposition
EP11179908A	Apr, 2023	Sandoz AG	Granted and Under Opposition
EP10703288A	Jan, 2021	Generics (U.K.) Limited	Granted and Under Opposition
EP10703288A	Jan, 2021	STADA Arzneimittel AG	Granted and Under Opposition
EP10703288A	Dec, 2020	ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.	Granted and Under Opposition
EP11194615A	Jun, 2020	ELKINGTON AND FIFE LLP	Granted and Under Opposition
EP10730454A	Dec, 2019	Generics [UK] Ltd	Granted and Under Opposition
EP10730454A	Dec, 2019	LEK Pharmaceuticals d.d.	Granted and Under Opposition
EP10730454A	Nov, 2019	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP09757601A	Aug, 2019	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP09757601A	Aug, 2019	Ter Meer Steinmeister & Partner Patentanwälte mbB	Granted and Under Opposition
EP09757601A	Aug, 2019	Generics (U.K.) Limited	Granted and Under Opposition
EP14715578A	Aug, 2019	Generics (U.K.) Limited	Granted and Under Opposition
EP14715578A	Aug, 2019	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP14715578A	Aug, 2019	ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.	Granted and Under Opposition
EP14715578A	Aug, 2019	Gillard, Richard Edward	Granted and Under Opposition
EP14715578A	Aug, 2019	Stada-Arzneimittel Aktiengesellschaft	Granted and Under Opposition
EP14715578A	Aug, 2019	EGIS Gyógyszergyár Zártkörüen Müködö Részvénytársaság	Granted and Under Opposition
EP14715578A	Aug, 2019	Alfred E. Tiefenbacher (GmbH & Co. KG)	Granted and Under Opposition
EP14715578A	Aug, 2019	KRKA, d.d., Novo mesto	Granted and Under Opposition
EP09728065A	Jun, 2019	isarpatent - Patent- und Rechtsanwälte Behnisch Barth Charles Hassa Peckmann und Partner mbB	Revoked
EP09728065A	Jun, 2019	Galenicum Health S.L.U.	Revoked
EP09728065A	Jun, 2019	Hexal AG	Revoked
EP09728065A	Jun, 2019	HGF Limited	Revoked
EP09757593A	Nov, 2018	Zentiva Group, a.s.	Granted and Under Opposition
EP09757593A	Nov, 2018	Generics (U.K.) Limited	Granted and Under Opposition
EP09757593A	Nov, 2018	Galenicum Health S.L.	Granted and Under Opposition
EP09757593A	Nov, 2018	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP08787264A	Jul, 2017	ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.	Granted and Under Opposition
EP08787264A	Jul, 2017	STADA Arzneimittel AG	Granted and Under Opposition
EP08787264A	Jul, 2017	Hexal AG	Granted and Under Opposition
EP08787264A	Jul, 2017	Generics (U.K.) Limited	Granted and Under Opposition
EP08756672A	Dec, 2016	FRKelly	Revoked
EP12155662A	Sep, 2016	LEK Pharmaceuticals d.d.	Patent maintained as amended
EP10175188A	Dec, 2015	Generics (UK) Limited	Revoked
EP10175188A	Dec, 2015	Galenicum Health S.L.	Revoked
EP10175188A	Dec, 2015	Hexal AG	Revoked
EP10175188A	Dec, 2015	STADA Arzneimittel AG	Revoked
EP10175188A	Dec, 2015	Teva Pharmaceutical Industries LTD.	Revoked
EP10175638A	Jul, 2015	Generics [UK] Limited (trading as Mylan)	Revoked
EP10175638A	Jul, 2015	STADA Arzneimittel AG	Revoked
EP10175638A	Jul, 2015	Hexal AG	Revoked
EP10175638A	Jul, 2015	Teva Pharmaceutical Industries Ltd.	Revoked
EP07728723A	Jan, 2015	Hexal AG	Revoked
EP03771959A	Jun, 2014	Maiwald Patentanwalts GmbH	Opposition rejected
EP03745781A	May, 2014	Actavis Group PTC ehf	Revoked
EP03745781A	May, 2014	Vossius & Partner	Revoked
EP03745781A	May, 2014	Teva UK Limited	Revoked
EP05737938A	Apr, 2014	Aechter, Bernd	Opposition rejected
EP03771959A	Oct, 2013	Actavis Group PTC ehf	Opposition rejected
EP05823930A	Aug, 2013	SANDOZ AG	Opposition rejected
EP03743368A	Apr, 2013	Sanovel IIaç San. ve Tic. A.S.	Patent maintained as amended
EP03743368A	Mar, 2013	Stötter, Gerd	Patent maintained as amended
EP07115663A	Oct, 2012	Sanovel IIaç San. ve Tic. A.S.	Revoked
EP07115663A	Oct, 2012	Stötter, Gerd	Revoked
EP05763065A	Aug, 2012	Dr. May, Mark Andrew	Patent maintained as amended
EP09153155A	Jul, 2012	PONS PATENTES Y MARCAS INTERNACIONAL, S.L.	Revoked
EP09153155A	Jul, 2012	Sanovel Ilac Sanayii ve Ticaret A.S.	Revoked
EP09153155A	Jul, 2012	Stötter, Gerd	Revoked
EP2004006768W	Apr, 2012	Knorr-Bremse Systeme für Nutzfahrzeuge GmbH	Revoked
EP05777774A	Aug, 2011	Teva Pharmaceutical Industries LTD.	Patent maintained as amended
EP05777774A	Aug, 2011	Sölch, Günter	Patent maintained as amended
EP04764411A	Jan, 2010	APOTEX INC.	Opposition rejected
EP04021889A	Apr, 2008	Merck & Co., Inc.	Revoked
EP04021889A	Apr, 2008	Sanofi-Aventis Deutschland GmbH	Revoked
EP04021889A	Apr, 2008	TEVA PHARMACEUTICAL INDUSTRIES LTD.	Revoked
EP04021889A	Apr, 2008	LES LABORATOIRES SERVIER	Revoked
EP01986599A	Dec, 2006	AstraZeneca AB	Patent maintained as amended
EP01986599A	Dec, 2006	PFIZER LIMITED	Patent maintained as amended
EP98947698A	Feb, 2006	Speedel Pharma AG	Patent maintained as amended

Boehringer Ingelheim's Family Patents

Boehringer Ingelheim drugs have patent protection in a total of 64 countries. It's US patent count contributes only to 11.4% of its total global patent coverage. 8 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Boehringer Ingelheim Drug List

Given below is the complete list of Boehringer Ingelheim's drugs and the patents protecting them.

1. Aggrenox

Aggrenox is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6015577	Pharmaceutical compositions containing dipyridamole or mopidamol and acetylsalicylic acid or the physiologically acceptable salts thereof, processes for preparing them and their use in treating clot formation	18 Jan, 2017 (8 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aggrenox's drug page

2. Aptivus

Aptivus is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6147095 (Pediatric)	Method for improving the pharmacokinetics of tipranavir	29 Apr, 2020 (5 years ago)	Expired
US5852195 (Pediatric)	Pyranone compounds useful to treat retroviral infections	22 Dec, 2019 (5 years ago)	Expired
US6147095	Method for improving the pharmacokinetics of tipranavir	29 Oct, 2019 (5 years ago)	Expired
US5852195	Pyranone compounds useful to treat retroviral infections	22 Jun, 2019 (5 years ago)	Expired
US6231887 (Pediatric)	Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation	27 Jan, 2019 (6 years ago)	Expired
US6231887	Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation	27 Jul, 2018 (6 years ago)	Expired
US6169181 (Pediatric)	Compounds useful to treat retroviral infections	06 Nov, 2014 (10 years ago)	Expired
US6169181	Compounds useful to treat retroviral infections	06 May, 2014 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aptivus's drug page

3. Atrovent Hfa

Atrovent Hfa is protected by 5 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8474447	Inhaler device	17 Jan, 2030 (4 years from now)	Active
US6739333	Stainless steel canister for propellant-driven metering aerosols	26 May, 2020 (4 years ago)	Expired
US6983743	Stainless steel canister for propellant-driven metering aerosols	26 May, 2020 (4 years ago)	Expired
US5683677	Medicinal aerosol formulations	04 Nov, 2014 (10 years ago)	Expired
US5676930	Stabilized medicinal aerosol solution formulations	14 Oct, 2014 (10 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Atrovent Hfa's drug page

4. Combivent

Combivent is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5603918	Aerosol composition of a salt of ipratropium and a salt of albuterol	09 Jun, 2015 (9 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Combivent's drug page

5. Combivent Respimat

Combivent Respimat is protected by 24 patents, out of which 19 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8733341	Atomizer and method of atomizing fluid with a nozzle rinsing mechanism	16 Oct, 2030 (5 years from now)	Active
US7837235	Device for clamping a fluidic component	13 Mar, 2028 (2 years from now)	Active
US9027967	Device for clamping a fluidic component	31 Mar, 2027 (1 year, 10 months from now)	Active
US7396341	Blocking device for a locking stressing mechanism having a spring-actuated output drive device	10 Oct, 2026 (1 year, 5 months from now)	Active
US7896264	Microstructured high pressure nozzle with built-in filter function	26 May, 2025 (16 days from now)	Active
US7284474	Piston-pumping system having o-ring seal properties	26 Aug, 2024 (8 months ago)	Expired
US7988001	Container provided with a pressure equalization opening	04 Aug, 2021 (3 years ago)	Expired
US6988496	Cartridge for a liquid	23 Feb, 2020 (5 years ago)	Expired
US7802568	Cartridge for a liquid	26 Feb, 2019 (6 years ago)	Expired
US6846413	Microstructured filter	28 Aug, 2018 (6 years ago)	Expired
US6977042	Microstructured filter	28 Aug, 2018 (6 years ago)	Expired
US6149054	Mechanical counter for a metering apparatus	19 Dec, 2016 (8 years ago)	Expired
US6453795	Locking mechanism for a spring-actuated device	05 Dec, 2016 (8 years ago)	Expired
US5964416	Device for producing high pressure in a fluid in miniature	04 Oct, 2016 (8 years ago)	Expired
US6176442	Device for mounting a component exposed to a pressurized fluid	04 Oct, 2016 (8 years ago)	Expired
US6726124	Device for producing high pressure in a fluid in miniature	04 Oct, 2016 (8 years ago)	Expired
US7104470	Device for producing high pressure in a fluid in miniature	04 Oct, 2016 (8 years ago)	Expired
US7246615	Atomising nozzle and filter and spray generating device	31 May, 2016 (8 years ago)	Expired
US5662271	Atomizing devices and methods	02 Sep, 2014 (10 years ago)	Expired
US5472143	Atomising nozzle and filter and spray generation device	29 Sep, 2013 (11 years ago)	Expired
US5911851	Atomizing nozzle and filter and spray generating device	29 Sep, 2013 (11 years ago)	Expired
US6007676	Atomizing nozzle and filter and spray generating device	29 Sep, 2013 (11 years ago)	Expired
US6503362	Atomizing nozzle an filter and spray generating device	29 Sep, 2013 (11 years ago)	Expired
US5497944	Atomising devices and methods	12 Mar, 2013 (12 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Combivent Respimat's drug page

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List

6. Gilotrif

Gilotrif is protected by 11 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10004743 (Pediatric)	Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient	05 Jan, 2031 (5 years from now)	Active
US10004743	Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient	05 Jul, 2030 (5 years from now)	Active
US8545884 (Pediatric)	Solid pharmaceutical formulations comprising BIBW 2992	19 Jun, 2030 (5 years from now)	Active
US8426586 (Pediatric)	Process for preparing amino crotonyl compounds	10 Apr, 2030 (4 years from now)	Active
US8545884	Solid pharmaceutical formulations comprising BIBW 2992	19 Dec, 2029 (4 years from now)	Active
US8426586	Process for preparing amino crotonyl compounds	10 Oct, 2029 (4 years from now)	Active
US9539258 (Pediatric)	Quinazoline derivatives for the treatment of cancer diseases	09 May, 2027 (1 year, 11 months from now)	Active
US9539258	Quinazoline derivatives for the treatment of cancer diseases	09 Nov, 2026 (1 year, 6 months from now)	Active
USRE43431 (Pediatric)	Quinazoline derivatives and pharmaceutical compositions containing them	13 Jul, 2026 (1 year, 2 months from now)	Active
USRE43431	Quinazoline derivatives and pharmaceutical compositions containing them	13 Jan, 2026 (8 months from now)	Active
US6251912	Substituted quinazoline derivatives	29 Jul, 2018 (6 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gilotrif's drug page

7. Glyxambi

Glyxambi is protected by 31 patents, out of which 7 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10258637 (Pediatric)	Pharmaceutical composition, methods for treating and uses thereof	03 Oct, 2034 (9 years from now)	Active
US11090323 (Pediatric)	Pharmaceutical composition, methods for treating and uses thereof	03 Oct, 2034 (9 years from now)	Active
US9949998	Pharmaceutical composition, methods for treating and uses thereof	11 Jun, 2034 (9 years from now)	Active
US10258637	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034 (8 years from now)	Active
US11090323	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034 (8 years from now)	Active
US11833166	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034 (8 years from now)	Active
US10406172	Pharmaceutical composition, methods for treating and uses thereof	15 Jun, 2030 (5 years from now)	Active
US8846695	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor	04 Jun, 2030 (5 years from now)	Active
US8551957 (Pediatric)	Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate	14 Apr, 2030 (4 years from now)	Active
US12115179	Pharmaceutical composition, methods for treating and uses thereof	11 Feb, 2030 (4 years from now)	Active
US8551957	Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate	14 Oct, 2029 (4 years from now)	Active
US7579449 (Pediatric)	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture	01 Feb, 2029 (3 years from now)	Active
US7579449	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture	01 Aug, 2028 (3 years from now)	Active
US11033552 (Pediatric)	DPP IV inhibitor formulations	04 Nov, 2027 (2 years from now)	Active
US8673927 (Pediatric)	Uses of DPP-IV inhibitors	04 Nov, 2027 (2 years from now)	Active
US7713938 (Pediatric)	Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments	15 Oct, 2027 (2 years from now)	Active
US11033552	DPP IV inhibitor formulations	04 May, 2027 (1 year, 11 months from now)	Active
US12178819	DPP IV inhibitor formulations	04 May, 2027 (1 year, 11 months from now)	Active
US8673927	Uses of DPP-IV inhibitors	04 May, 2027 (1 year, 11 months from now)	Active
US9173859	Uses of DPP IV inhibitors	04 May, 2027 (1 year, 11 months from now)	Active
US7713938	Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments	15 Apr, 2027 (1 year, 11 months from now)	Active
US8883805 (Pediatric)	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	26 May, 2026 (1 year, 16 days from now)	Active
US8883805	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	26 Nov, 2025 (6 months from now)	Active
US7407955 (Pediatric)	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	02 Nov, 2025 (5 months from now)	Active
US7407955	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	02 May, 2025 (7 days ago)	Expired
US8119648	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	12 Aug, 2023 (1 year, 8 months ago)	Expired
US8178541	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	12 Aug, 2023 (1 year, 8 months ago)	Expired
US6890898	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (6 years ago)	Expired
US7078381	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (6 years ago)	Expired
US7459428	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (6 years ago)	Expired
US6303661	Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals	24 Apr, 2017 (8 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Glyxambi's drug page

8. Jardiance

Jardiance is protected by 19 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US9949998 (Pediatric)	Pharmaceutical composition, methods for treating and uses thereof	11 Dec, 2034 (9 years from now)	Active
US9949997 (Pediatric)	Pharmaceutical composition, methods for treating and uses thereof	17 Nov, 2034 (9 years from now)	Active
US10258637 (Pediatric)	Pharmaceutical composition, methods for treating and uses thereof	03 Oct, 2034 (9 years from now)	Active
US11090323 (Pediatric)	Pharmaceutical composition, methods for treating and uses thereof	03 Oct, 2034 (9 years from now)	Active
US9949998	Pharmaceutical composition, methods for treating and uses thereof	11 Jun, 2034 (9 years from now)	Active
US9949997	Pharmaceutical composition, methods for treating and uses thereof	17 May, 2034 (9 years from now)	Active
US10258637	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034 (8 years from now)	Active
US11090323	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034 (8 years from now)	Active
US11666590	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034 (8 years from now)	Active
US11813275	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034 (8 years from now)	Active
US11833166	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034 (8 years from now)	Active
US10406172	Pharmaceutical composition, methods for treating and uses thereof	15 Jun, 2030 (5 years from now)	Active
US8551957 (Pediatric)	Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate	14 Apr, 2030 (4 years from now)	Active
US12115179	Pharmaceutical composition, methods for treating and uses thereof	11 Feb, 2030 (4 years from now)	Active
US8551957	Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate	14 Oct, 2029 (4 years from now)	Active
US7579449 (Pediatric)	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture	01 Feb, 2029 (3 years from now)	Active
US7579449	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture	01 Aug, 2028 (3 years from now)	Active
US7713938 (Pediatric)	Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments	15 Oct, 2027 (2 years from now)	Active
US7713938	Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments	15 Apr, 2027 (1 year, 11 months from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jardiance's drug page

9. Jentadueto

Jentadueto is protected by 24 patents, out of which 7 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8846695 (Pediatric)	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor	04 Dec, 2030 (5 years from now)	Active
US9155705 (Pediatric)	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	21 Nov, 2030 (5 years from now)	Active
US8846695	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor	04 Jun, 2030 (5 years from now)	Active
US9155705	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	21 May, 2030 (5 years from now)	Active
US11911388	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug	10 Apr, 2030 (4 years from now)	Active
US10022379 (Pediatric)	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	02 Oct, 2029 (4 years from now)	Active
US10973827 (Pediatric)	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	02 Oct, 2029 (4 years from now)	Active
US9415016 (Pediatric)	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	02 Oct, 2029 (4 years from now)	Active
US10022379	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	02 Apr, 2029 (3 years from now)	Active
US10973827	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	02 Apr, 2029 (3 years from now)	Active
US9415016	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	02 Apr, 2029 (3 years from now)	Active
US8673927 (Pediatric)	Uses of DPP-IV inhibitors	04 Nov, 2027 (2 years from now)	Active
US8673927	Uses of DPP-IV inhibitors	04 May, 2027 (1 year, 11 months from now)	Active
US9173859	Uses of DPP IV inhibitors	04 May, 2027 (1 year, 11 months from now)	Active
US8883805 (Pediatric)	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	26 May, 2026 (1 year, 16 days from now)	Active
US8883805	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	26 Nov, 2025 (6 months from now)	Active
US7407955 (Pediatric)	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	02 Nov, 2025 (5 months from now)	Active
US7407955	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	02 May, 2025 (7 days ago)	Expired
US8119648	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	12 Aug, 2023 (1 year, 8 months ago)	Expired
US8178541	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	12 Aug, 2023 (1 year, 8 months ago)	Expired
US6890898	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (6 years ago)	Expired
US7078381	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (6 years ago)	Expired
US7459428	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (6 years ago)	Expired
US6303661	Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals	24 Apr, 2017 (8 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jentadueto's drug page

10. Jentadueto Xr

Jentadueto Xr is protected by 27 patents, out of which 10 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US9555001 (Pediatric)	Pharmaceutical composition and uses thereof	06 Sep, 2033 (8 years from now)	Active
US9555001	Pharmaceutical composition and uses thereof	06 Mar, 2033 (7 years from now)	Active
US9155705 (Pediatric)	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	21 Nov, 2030 (5 years from now)	Active
US8846695	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor	04 Jun, 2030 (5 years from now)	Active
US9155705	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	21 May, 2030 (5 years from now)	Active
US11911388	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug	10 Apr, 2030 (4 years from now)	Active
US10022379 (Pediatric)	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	02 Oct, 2029 (4 years from now)	Active
US9415016 (Pediatric)	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	02 Oct, 2029 (4 years from now)	Active
US10022379	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	02 Apr, 2029 (3 years from now)	Active
US9415016	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	02 Apr, 2029 (3 years from now)	Active
US8673927 (Pediatric)	Uses of DPP-IV inhibitors	04 Nov, 2027 (2 years from now)	Active
US9173859 (Pediatric)	Uses of DPP IV inhibitors	04 Nov, 2027 (2 years from now)	Active
US8673927	Uses of DPP-IV inhibitors	04 May, 2027 (1 year, 11 months from now)	Active
US9173859	Uses of DPP IV inhibitors	04 May, 2027 (1 year, 11 months from now)	Active
US8883805 (Pediatric)	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	26 May, 2026 (1 year, 16 days from now)	Active
US8883805	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	26 Nov, 2025 (6 months from now)	Active
US7407955 (Pediatric)	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	02 Nov, 2025 (5 months from now)	Active
US7407955	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	02 May, 2025 (7 days ago)	Expired
US8119648	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	12 Aug, 2023 (1 year, 8 months ago)	Expired
US8178541	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	12 Aug, 2023 (1 year, 8 months ago)	Expired
US6488962	Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms	20 Jun, 2020 (4 years ago)	Expired
US6890898	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (6 years ago)	Expired
US7078381	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (6 years ago)	Expired
US7459428	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (6 years ago)	Expired
US6303661	Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals	24 Apr, 2017 (8 years ago)	Expired
US6340475	Extending the duration of drug release within the stomach during the fed mode	19 Sep, 2016 (8 years ago)	Expired
US6635280	Extending the duration of drug release within the stomach during the fed mode	19 Sep, 2016 (8 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jentadueto Xr's drug page

11. Micardis

Micardis is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8003679	Use of inhibitors of the renin-angiotensin system	06 Oct, 2022 (2 years ago)	Expired
US7998953	Use of inhibitors of the renin-angiotensin system	06 Jun, 2020 (4 years ago)	Expired
US6358986	Polymorphs of telmisartan	10 Jan, 2020 (5 years ago)	Expired
US5591762	Benzimidazoles useful as angiotensin-11 antagonists	07 Jan, 2014 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Micardis's drug page

12. Micardis Hct

Micardis Hct is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6358986	Polymorphs of telmisartan	10 Jan, 2020 (5 years ago)	Expired
US5591762	Benzimidazoles useful as angiotensin-11 antagonists	07 Jan, 2014 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Micardis Hct's drug page

13. Mirapex

Mirapex is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6001861	Use of pramipexole in the treatment of restless legs syndrome	16 Jan, 2018 (7 years ago)	Expired
US6194445	Use of pramipexole in the treatment of restless legs syndrome	16 Jan, 2018 (7 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mirapex's drug page

14. Mirapex Er

Mirapex Er is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8679533	Pramipexole once-daily dosage form	08 Sep, 2029 (4 years from now)	Active
US7695734	Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof	26 Apr, 2028 (2 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mirapex Er's drug page

15. Ofev

Ofev is protected by 10 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US9907756 (Pediatric)	Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative	07 Dec, 2029 (4 years from now)	Active
US10105323 (Pediatric)	Pharmaceutical dosage form for immediate release of an indolinone derivative	04 Dec, 2029 (4 years from now)	Active
US9907756	Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative	07 Jun, 2029 (4 years from now)	Active
US10105323	Pharmaceutical dosage form for immediate release of an indolinone derivative	04 Jun, 2029 (4 years from now)	Active
US10154990 (Pediatric)	Medicaments for the treatment or prevention of fibrotic diseases	08 Jul, 2026 (1 year, 1 month from now)	Active
US6762180 (Pediatric)	Substituted indolines which inhibit receptor tyrosine kinases	01 Apr, 2026 (10 months from now)	Active
US10154990	Medicaments for the treatment or prevention of fibrotic diseases	08 Jan, 2026 (7 months from now)	Active
US6762180	Substituted indolines which inhibit receptor tyrosine kinases	01 Oct, 2025 (4 months from now)	Active
US7989474	Use of Lck inhibitors for treatment of immunologic diseases	06 Apr, 2024 (1 year, 1 month ago)	Expired
US7119093	3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition	21 Feb, 2024 (1 year, 2 months ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ofev's drug page

16. Pradaxa

Pradaxa is protected by 11 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US9034822 (Pediatric)	Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds	20 Jul, 2031 (6 years from now)	Active
US9034822	Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds	20 Jan, 2031 (5 years from now)	Active
US7866474 (Pediatric)	Film container	02 Mar, 2028 (2 years from now)	Active
US7866474	Film container	31 Aug, 2027 (2 years from now)	Active
US7932273 (Pediatric)	3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament	07 Mar, 2026 (9 months from now)	Active
US7932273	3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament	07 Sep, 2025 (3 months from now)	Active
US9925174 (Pediatric)	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof	14 Dec, 2023 (1 year, 4 months ago)	Expired
US9925174	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof	14 Jun, 2023 (1 year, 10 months ago)	Expired
US6087380 (Pediatric)	Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions	28 Jun, 2022 (2 years ago)	Expired
US6087380	Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions	28 Dec, 2021 (3 years ago)	Expired
US6087380	Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions	18 Feb, 2018 (7 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pradaxa's drug page

17. Spiriva

Spiriva is protected by 20 patents, out of which 15 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US9010323	Inhaler and sieve for an inhaler	19 Apr, 2030 (4 years from now)	Active
US7694676 (Pediatric)	Dry powder inhaler	12 Sep, 2027 (2 years from now)	Active
US7694676	Dry powder inhaler	12 Mar, 2027 (1 year, 10 months from now)	Active
US8022082 (Pediatric)	Method for the administration of an anticholinergic by inhalation	19 Jul, 2026 (1 year, 2 months from now)	Active
US8022082	Method for the administration of an anticholinergic by inhalation	19 Jan, 2026 (8 months from now)	Active
US7070800 (Pediatric)	Inhalable powder containing tiotropium	22 Jul, 2022 (2 years ago)	Expired
USRE38912 (Pediatric)	Process for preparing powder formulations	11 Apr, 2022 (3 years ago)	Expired
US6777423 (Pediatric)	Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions	24 Mar, 2022 (3 years ago)	Expired
US6908928 (Pediatric)	Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions	24 Mar, 2022 (3 years ago)	Expired
US7309707 (Pediatric)	Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament	24 Mar, 2022 (3 years ago)	Expired
US7642268 (Pediatric)	Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament	24 Mar, 2022 (3 years ago)	Expired
US7070800	Inhalable powder containing tiotropium	22 Jan, 2022 (3 years ago)	Expired
USRE38912	Process for preparing powder formulations	11 Oct, 2021 (3 years ago)	Expired
US6777423	Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions	24 Sep, 2021 (3 years ago)	Expired
US6908928	Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions	24 Sep, 2021 (3 years ago)	Expired
US7309707	Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament	24 Sep, 2021 (3 years ago)	Expired
US7642268	Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament	24 Sep, 2021 (3 years ago)	Expired
USRE39820 (Pediatric)	Esters of thienyl carboxylic acids and amino alcohols and their quaternization products	30 Jul, 2018 (6 years ago)	Expired
USRE39820	Esters of thienyl carboxylic acids and amino alcohols and their quaternization products	30 Jan, 2018 (7 years ago)	Expired
US5478578	Powders for inhalation	26 Dec, 2012 (12 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Spiriva's drug page

18. Spiriva Respimat

Spiriva Respimat is protected by 39 patents, out of which 29 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8733341 (Pediatric)	Atomizer and method of atomizing fluid with a nozzle rinsing mechanism	16 Apr, 2031 (5 years from now)	Active
US8733341	Atomizer and method of atomizing fluid with a nozzle rinsing mechanism	16 Oct, 2030 (5 years from now)	Active
US7837235 (Pediatric)	Device for clamping a fluidic component	13 Sep, 2028 (3 years from now)	Active
US7837235	Device for clamping a fluidic component	13 Mar, 2028 (2 years from now)	Active
US9027967 (Pediatric)	Device for clamping a fluidic component	30 Sep, 2027 (2 years from now)	Active
US7396341 (Pediatric)	Blocking device for a locking stressing mechanism having a spring-actuated output drive device	10 Apr, 2027 (1 year, 10 months from now)	Active
US9027967	Device for clamping a fluidic component	31 Mar, 2027 (1 year, 10 months from now)	Active
US7396341	Blocking device for a locking stressing mechanism having a spring-actuated output drive device	10 Oct, 2026 (1 year, 5 months from now)	Active
US7896264 (Pediatric)	Microstructured high pressure nozzle with built-in filter function	26 Nov, 2025 (6 months from now)	Active
US7896264	Microstructured high pressure nozzle with built-in filter function	26 May, 2025 (16 days from now)	Active
US7284474 (Pediatric)	Piston-pumping system having o-ring seal properties	26 Feb, 2025 (2 months ago)	Expired
US7284474	Piston-pumping system having o-ring seal properties	26 Aug, 2024 (8 months ago)	Expired
US7988001 (Pediatric)	Container provided with a pressure equalization opening	04 Feb, 2022 (3 years ago)	Expired
US7988001	Container provided with a pressure equalization opening	04 Aug, 2021 (3 years ago)	Expired
US6988496 (Pediatric)	Cartridge for a liquid	23 Aug, 2020 (4 years ago)	Expired
US6988496	Cartridge for a liquid	23 Feb, 2020 (5 years ago)	Expired
US7802568 (Pediatric)	Cartridge for a liquid	26 Aug, 2019 (5 years ago)	Expired
US6846413 (Pediatric)	Microstructured filter	28 Feb, 2019 (6 years ago)	Expired
US6977042 (Pediatric)	Microstructured filter	28 Feb, 2019 (6 years ago)	Expired
US7802568	Cartridge for a liquid	26 Feb, 2019 (6 years ago)	Expired
US6846413	Microstructured filter	28 Aug, 2018 (6 years ago)	Expired
US6977042	Microstructured filter	28 Aug, 2018 (6 years ago)	Expired
USRE39820 (Pediatric)	Esters of thienyl carboxylic acids and amino alcohols and their quaternization products	30 Jul, 2018 (6 years ago)	Expired
USRE39820	Esters of thienyl carboxylic acids and amino alcohols and their quaternization products	30 Jan, 2018 (7 years ago)	Expired
US6149054 (Pediatric)	Mechanical counter for a metering apparatus	16 Jun, 2017 (7 years ago)	Expired
US6453795 (Pediatric)	Locking mechanism for a spring-actuated device	05 Jun, 2017 (7 years ago)	Expired
US5964416 (Pediatric)	Device for producing high pressure in a fluid in miniature	04 Apr, 2017 (8 years ago)	Expired
US6726124 (Pediatric)	Device for producing high pressure in a fluid in miniature	04 Apr, 2017 (8 years ago)	Expired
US7104470 (Pediatric)	Device for producing high pressure in a fluid in miniature	04 Apr, 2017 (8 years ago)	Expired
US6149054	Mechanical counter for a metering apparatus	16 Dec, 2016 (8 years ago)	Expired
US6453795	Locking mechanism for a spring-actuated device	05 Dec, 2016 (8 years ago)	Expired
US6176442 (Pediatric)	Device for mounting a component exposed to a pressurized fluid	01 Dec, 2016 (8 years ago)	Expired
US7246615 (Pediatric)	Atomising nozzle and filter and spray generating device	01 Dec, 2016 (8 years ago)	Expired
US5964416	Device for producing high pressure in a fluid in miniature	04 Oct, 2016 (8 years ago)	Expired
US6726124	Device for producing high pressure in a fluid in miniature	04 Oct, 2016 (8 years ago)	Expired
US7104470	Device for producing high pressure in a fluid in miniature	04 Oct, 2016 (8 years ago)	Expired
US6176242	Method of treating manic depression by brain infusion	31 May, 2016 (8 years ago)	Expired
US6176442	Device for mounting a component exposed to a pressurized fluid	31 May, 2016 (8 years ago)	Expired
US7246615	Atomising nozzle and filter and spray generating device	31 May, 2016 (8 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Spiriva Respimat's drug page

19. Stiolto Respimat

Stiolto Respimat is protected by 34 patents, out of which 24 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8733341	Atomizer and method of atomizing fluid with a nozzle rinsing mechanism	16 Oct, 2030 (5 years from now)	Active
US7837235 (Pediatric)	Device for clamping a fluidic component	13 Sep, 2028 (3 years from now)	Active
US7837235	Device for clamping a fluidic component	13 Mar, 2028 (2 years from now)	Active
US7396341 (Pediatric)	Blocking device for a locking stressing mechanism having a spring-actuated output drive device	10 Apr, 2027 (1 year, 10 months from now)	Active
US9027967	Device for clamping a fluidic component	31 Mar, 2027 (1 year, 10 months from now)	Active
US7727984	Medicaments for the treatment of chronic obstructive pulmonary disease	19 Jan, 2027 (1 year, 8 months from now)	Active
US7396341	Blocking device for a locking stressing mechanism having a spring-actuated output drive device	10 Oct, 2026 (1 year, 5 months from now)	Active
US7896264	Microstructured high pressure nozzle with built-in filter function	26 May, 2025 (16 days from now)	Active
US7220742	Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments	12 May, 2025 (2 days from now)	Active
US8034809	Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments	12 May, 2025 (2 days from now)	Active
US7284474 (Pediatric)	Piston-pumping system having o-ring seal properties	26 Feb, 2025 (2 months ago)	Expired
US7284474	Piston-pumping system having o-ring seal properties	26 Aug, 2024 (8 months ago)	Expired
US7056916	Medicaments for the treatment of chronic obstructive pulmonary disease	07 Dec, 2023 (1 year, 5 months ago)	Expired
US7491719	Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments	10 Nov, 2023 (1 year, 5 months ago)	Expired
US7786111	Medicaments for the treatment of chronic obstructive pulmonary disease	10 Nov, 2023 (1 year, 5 months ago)	Expired
US8044046	Medicaments for the treatment of chronic obstructive pulmonary disease	10 Nov, 2023 (1 year, 5 months ago)	Expired
US7988001	Container provided with a pressure equalization opening	04 Aug, 2021 (3 years ago)	Expired
US6988496 (Pediatric)	Cartridge for a liquid	23 Aug, 2020 (4 years ago)	Expired
US6988496	Cartridge for a liquid	23 Feb, 2020 (5 years ago)	Expired
US7802568 (Pediatric)	Cartridge for a liquid	26 Aug, 2019 (5 years ago)	Expired
US6846413 (Pediatric)	Microstructured filter	28 Feb, 2019 (6 years ago)	Expired
US6977042 (Pediatric)	Microstructured filter	28 Feb, 2019 (6 years ago)	Expired
US7802568	Cartridge for a liquid	26 Feb, 2019 (6 years ago)	Expired
US6846413	Microstructured filter	28 Aug, 2018 (6 years ago)	Expired
US6977042	Microstructured filter	28 Aug, 2018 (6 years ago)	Expired
USRE39820	Esters of thienyl carboxylic acids and amino alcohols and their quaternization products	30 Jan, 2018 (7 years ago)	Expired
US6149054 (Pediatric)	Mechanical counter for a metering apparatus	19 Jun, 2017 (7 years ago)	Expired
US6149054	Mechanical counter for a metering apparatus	19 Dec, 2016 (8 years ago)	Expired
US6453795	Locking mechanism for a spring-actuated device	05 Dec, 2016 (8 years ago)	Expired
US5964416	Device for producing high pressure in a fluid in miniature	04 Oct, 2016 (8 years ago)	Expired
US6176442	Device for mounting a component exposed to a pressurized fluid	04 Oct, 2016 (8 years ago)	Expired
US6726124	Device for producing high pressure in a fluid in miniature	04 Oct, 2016 (8 years ago)	Expired
US7104470	Device for producing high pressure in a fluid in miniature	04 Oct, 2016 (8 years ago)	Expired
US7246615	Atomising nozzle and filter and spray generating device	31 May, 2016 (8 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Stiolto Respimat's drug page

20. Striverdi Respimat

Striverdi Respimat is protected by 25 patents, out of which 17 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8733341	Atomizer and method of atomizing fluid with a nozzle rinsing mechanism	16 Oct, 2030 (5 years from now)	Active
US7837235	Device for clamping a fluidic component	13 Mar, 2028 (2 years from now)	Active
US9027967	Device for clamping a fluidic component	31 Mar, 2027 (1 year, 10 months from now)	Active
US7727984	Medicaments for the treatment of chronic obstructive pulmonary disease	19 Jan, 2027 (1 year, 8 months from now)	Active
US7396341	Blocking device for a locking stressing mechanism having a spring-actuated output drive device	10 Oct, 2026 (1 year, 5 months from now)	Active
US7896264	Microstructured high pressure nozzle with built-in filter function	26 May, 2025 (16 days from now)	Active
US7220742	Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments	12 May, 2025 (2 days from now)	Active
US8034809	Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments	12 May, 2025 (2 days from now)	Active
US7284474	Piston-pumping system having o-ring seal properties	26 Aug, 2024 (8 months ago)	Expired
US7056916	Medicaments for the treatment of chronic obstructive pulmonary disease	07 Dec, 2023 (1 year, 5 months ago)	Expired
US7491719	Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments	10 Nov, 2023 (1 year, 5 months ago)	Expired
US7786111	Medicaments for the treatment of chronic obstructive pulmonary disease	10 Nov, 2023 (1 year, 5 months ago)	Expired
US8044046	Medicaments for the treatment of chronic obstructive pulmonary disease	10 Nov, 2023 (1 year, 5 months ago)	Expired
US7988001	Container provided with a pressure equalization opening	04 Aug, 2021 (3 years ago)	Expired
US6988496	Cartridge for a liquid	23 Feb, 2020 (5 years ago)	Expired
US7802568	Cartridge for a liquid	26 Feb, 2019 (6 years ago)	Expired
US6846413	Microstructured filter	28 Aug, 2018 (6 years ago)	Expired
US6977042	Microstructured filter	28 Aug, 2018 (6 years ago)	Expired
US6149054	Mechanical counter for a metering apparatus	19 Dec, 2016 (8 years ago)	Expired
US6453795	Locking mechanism for a spring-actuated device	05 Dec, 2016 (8 years ago)	Expired
US5964416	Device for producing high pressure in a fluid in miniature	04 Oct, 2016 (8 years ago)	Expired
US6176442	Device for mounting a component exposed to a pressurized fluid	04 Oct, 2016 (8 years ago)	Expired
US6726124	Device for producing high pressure in a fluid in miniature	04 Oct, 2016 (8 years ago)	Expired
US7104470	Device for producing high pressure in a fluid in miniature	04 Oct, 2016 (8 years ago)	Expired
US7246615	Atomising nozzle and filter and spray generating device	31 May, 2016 (8 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Striverdi Respimat's drug page

21. Synjardy

Synjardy is protected by 15 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US9949997 (Pediatric)	Pharmaceutical composition, methods for treating and uses thereof	17 Nov, 2034 (9 years from now)	Active
US10258637 (Pediatric)	Pharmaceutical composition, methods for treating and uses thereof	03 Oct, 2034 (9 years from now)	Active
US11090323 (Pediatric)	Pharmaceutical composition, methods for treating and uses thereof	03 Oct, 2034 (9 years from now)	Active
US9949997	Pharmaceutical composition, methods for treating and uses thereof	17 May, 2034 (9 years from now)	Active
US10258637	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034 (8 years from now)	Active
US11090323	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034 (8 years from now)	Active
US11813275	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034 (8 years from now)	Active
US11833166	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034 (8 years from now)	Active
US10610489 (Pediatric)	Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof	30 Mar, 2031 (5 years from now)	Active
US10610489	Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof	30 Sep, 2030 (5 years from now)	Active
US12115179	Pharmaceutical composition, methods for treating and uses thereof	11 Feb, 2030 (4 years from now)	Active
US7579449 (Pediatric)	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture	01 Feb, 2029 (3 years from now)	Active
US7579449	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture	01 Aug, 2028 (3 years from now)	Active
US7713938 (Pediatric)	Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments	15 Oct, 2027 (2 years from now)	Active
US7713938	Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments	15 Apr, 2027 (1 year, 11 months from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Synjardy's drug page

22. Synjardy Xr

Synjardy Xr is protected by 18 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US9949998 (Pediatric)	Pharmaceutical composition, methods for treating and uses thereof	11 Dec, 2034 (9 years from now)	Active
US9949997 (Pediatric)	Pharmaceutical composition, methods for treating and uses thereof	17 Nov, 2034 (9 years from now)	Active
US10258637 (Pediatric)	Pharmaceutical composition, methods for treating and uses thereof	03 Oct, 2034 (9 years from now)	Active
US11090323 (Pediatric)	Pharmaceutical composition, methods for treating and uses thereof	03 Oct, 2034 (9 years from now)	Active
US9949998	Pharmaceutical composition, methods for treating and uses thereof	11 Jun, 2034 (9 years from now)	Active
US9949997	Pharmaceutical composition, methods for treating and uses thereof	17 May, 2034 (9 years from now)	Active
US10258637	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034 (8 years from now)	Active
US11090323	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034 (8 years from now)	Active
US11813275	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034 (8 years from now)	Active
US11833166	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034 (8 years from now)	Active
US10596120 (Pediatric)	Pharmaceutical compositions	07 Sep, 2032 (7 years from now)	Active
US10596120	Pharmaceutical compositions	07 Mar, 2032 (6 years from now)	Active
US12115179	Pharmaceutical composition, methods for treating and uses thereof	11 Feb, 2030 (4 years from now)	Active
US7579449 (Pediatric)	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture	01 Feb, 2029 (3 years from now)	Active
US7579449	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture	01 Aug, 2028 (3 years from now)	Active
US7713938 (Pediatric)	Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments	15 Oct, 2027 (2 years from now)	Active
US7713938	Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments	15 Apr, 2027 (1 year, 11 months from now)	Active
US6488962	Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms	20 Jun, 2020 (4 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Synjardy Xr's drug page

23. Tradjenta

Tradjenta is protected by 25 patents, out of which 7 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8853156 (Pediatric)	Treatment for diabetes in patients inappropriate for metformin therapy	05 Sep, 2031 (6 years from now)	Active
US8853156	Treatment for diabetes in patients inappropriate for metformin therapy	05 Mar, 2031 (5 years from now)	Active
US8846695 (Pediatric)	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor	04 Dec, 2030 (5 years from now)	Active
US8846695	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor	04 Jun, 2030 (5 years from now)	Active
US11911388	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug	10 Apr, 2030 (4 years from now)	Active
US10034877 (Pediatric)	Treatment for diabetes in patients inappropriate for metformin therapy	05 Feb, 2030 (4 years from now)	Active
US9486526 (Pediatric)	Treatment for diabetes in patients inappropriate for metformin therapy	05 Feb, 2030 (4 years from now)	Active
US10034877	Treatment for diabetes in patients inappropriate for metformin therapy	05 Aug, 2029 (4 years from now)	Active
US9486526	Treatment for diabetes in patients inappropriate for metformin therapy	05 Aug, 2029 (4 years from now)	Active
US11033552 (Pediatric)	DPP IV inhibitor formulations	04 Nov, 2027 (2 years from now)	Active
US8673927 (Pediatric)	Uses of DPP-IV inhibitors	04 Nov, 2027 (2 years from now)	Active
US11033552	DPP IV inhibitor formulations	04 May, 2027 (1 year, 11 months from now)	Active
US12178819	DPP IV inhibitor formulations	04 May, 2027 (1 year, 11 months from now)	Active
US8673927	Uses of DPP-IV inhibitors	04 May, 2027 (1 year, 11 months from now)	Active
US9173859	Uses of DPP IV inhibitors	04 May, 2027 (1 year, 11 months from now)	Active
US8883805 (Pediatric)	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	26 May, 2026 (1 year, 16 days from now)	Active
US8883805	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	26 Nov, 2025 (6 months from now)	Active
US7407955 (Pediatric)	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	02 Nov, 2025 (5 months from now)	Active
US7407955	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	02 May, 2025 (7 days ago)	Expired
US8119648	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	12 Aug, 2023 (1 year, 8 months ago)	Expired
US8178541	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	12 Aug, 2023 (1 year, 8 months ago)	Expired
US6890898	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (6 years ago)	Expired
US7078381	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (6 years ago)	Expired
US7459428	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (6 years ago)	Expired
US6303661	Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals	24 Apr, 2017 (8 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tradjenta's drug page

24. Trijardy Xr

Trijardy Xr is protected by 29 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US9949998 (Pediatric)	Pharmaceutical composition, methods for treating and uses thereof	11 Dec, 2034 (9 years from now)	Active
US10258637 (Pediatric)	Pharmaceutical composition, methods for treating and uses thereof	03 Oct, 2034 (9 years from now)	Active
US11090323 (Pediatric)	Pharmaceutical composition, methods for treating and uses thereof	03 Oct, 2034 (9 years from now)	Active
US9949998	Pharmaceutical composition, methods for treating and uses thereof	11 Jun, 2034 (9 years from now)	Active
US10258637	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034 (8 years from now)	Active
US11090323	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034 (8 years from now)	Active
US11833166	Pharmaceutical composition, methods for treating and uses thereof	03 Apr, 2034 (8 years from now)	Active
US10596120	Pharmaceutical compositions	07 Mar, 2032 (6 years from now)	Active
US11564886	Pharmaceutical compositions	07 Mar, 2032 (6 years from now)	Active
US10406172	Pharmaceutical composition, methods for treating and uses thereof	15 Jun, 2030 (5 years from now)	Active
US9155705	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	21 May, 2030 (5 years from now)	Active
US8551957 (Pediatric)	Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate	14 Apr, 2030 (4 years from now)	Active
US12115179	Pharmaceutical composition, methods for treating and uses thereof	11 Feb, 2030 (4 years from now)	Active
US8551957	Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate	14 Oct, 2029 (4 years from now)	Active
US10022379	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	02 Apr, 2029 (3 years from now)	Active
US9415016	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	02 Apr, 2029 (3 years from now)	Active
US7579449 (Pediatric)	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture	01 Feb, 2029 (3 years from now)	Active
US7579449	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture	01 Aug, 2028 (3 years from now)	Active
US7713938 (Pediatric)	Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments	15 Oct, 2027 (2 years from now)	Active
US8673927	Uses of DPP-IV inhibitors	04 May, 2027 (1 year, 11 months from now)	Active
US9173859	Uses of DPP IV inhibitors	04 May, 2027 (1 year, 11 months from now)	Active
US7713938	Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments	15 Apr, 2027 (1 year, 11 months from now)	Active
US8883805 (Pediatric)	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	26 May, 2026 (1 year, 16 days from now)	Active
US8883805	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	26 Nov, 2025 (6 months from now)	Active
US7407955 (Pediatric)	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	02 Nov, 2025 (5 months from now)	Active
US7407955	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	02 May, 2025 (7 days ago)	Expired
US8119648	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	12 Aug, 2023 (1 year, 8 months ago)	Expired
US8178541	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	12 Aug, 2023 (1 year, 8 months ago)	Expired
US6488962	Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms	20 Jun, 2020 (4 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trijardy Xr's drug page

25. Twynsta

Twynsta is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5591762	Benzimidazoles useful as angiotensin-11 antagonists	07 Jan, 2014 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Twynsta's drug page

26. Viramune Xr

Viramune Xr is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8460704	Extended release formulation of nevirapine	12 Mar, 2029 (3 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Viramune Xr's drug page

Pharsight

Pharsight

Boehringer Ingelheim Drug Patent Portfolio

Latest Legal Activities on Boehringer Ingelheim's Drug Patents

Boehringer Ingelheim's Drug Patent Litigations

Boehringer Ingelheim Drug Patents' Oppositions Filed in EPO

Boehringer Ingelheim's Family Patents

Boehringer Ingelheim Drug List

1. Aggrenox

2. Aptivus

3. Atrovent Hfa

4. Combivent

5. Combivent Respimat

Explore Our Curated Drug Screens

6. Gilotrif

7. Glyxambi

8. Jardiance

9. Jentadueto

10. Jentadueto Xr

11. Micardis

12. Micardis Hct

13. Mirapex

14. Mirapex Er

15. Ofev

16. Pradaxa

17. Spiriva

18. Spiriva Respimat

19. Stiolto Respimat

20. Striverdi Respimat

21. Synjardy

22. Synjardy Xr

23. Tradjenta

24. Trijardy Xr

25. Twynsta

26. Viramune Xr

Boehringer Ingelheim News

Have Questions?

Pharsight

Pharsight

Latest Legal Activities on Boehringer Ingelheim's Drug Patents

Boehringer Ingelheim's Drug Patent Litigations

Boehringer Ingelheim Drug Patents' Oppositions Filed in EPO

Boehringer Ingelheim's Family Patents

Boehringer Ingelheim Drug List

Explore Our Curated Drug Screens

Boehringer Ingelheim News

Related content

Have Questions?